ARDX
Ardelyx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.80B
P/E Ratio
—
EPS
$-0.26
Beta
0.61
52W High
$8.40
52W Low
$3.21
50-Day MA
$6.04
200-Day MA
$5.97
Dividend Yield
—
Profit Margin
-13.60%
Forward P/E
38.17
PEG Ratio
-0.08
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Fundamentals
| Revenue (TTM) | $427.68M |
| Gross Profit (TTM) | $318.86M |
| EBITDA | $-34.05M |
| Operating Margin | -34.70% |
| Return on Equity | -39.50% |
| Return on Assets | -5.11% |
| Revenue/Share (TTM) | $1.76 |
| Book Value | $0.68 |
| Price-to-Book | 11.43 |
| Price-to-Sales (TTM) | 4.22 |
| EV/Revenue | 3.901 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 27.50% |
| Shares Outstanding | $247.03M |
| Float | $219.28M |
| % Insiders | 3.22% |
| % Institutions | 70.90% |
Historical Volatility
HV 10-Day
63.40%
HV 20-Day
47.62%
HV 30-Day
48.69%
HV 60-Day
64.18%
HV Rank
27.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($16.33 target)
1
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026